Produced by: NICE - National Institute for Health and Clinical Excellence, June 2006. Technology Appraisal Guidance 112.

Purpose: Guidance for the NHS in England and Wales on the use of aromatase inhibitors for the treatment for early oestrogen-receptor positive breast cancer.

Link to website: www.nice.org.uk/TA112

Produced by: NICE - National Institute for Health and Clinical Excellence. Interventional procedure guidance 147 (IPG147).

Purpose: Full guidance to the NHS in England, Wales, Scotland and Northern Ireland on endoscopic axillary lymph node retrieval for breast cancer. Describes the procedure and reviews its indications, safety and efficacy.

Can be obtained from: The full guidance, interventional procedure overview and public information leaflet are available to download from the website.

Link to website: www.nice.org.uk/guidance/IPG147

Produced by: Scottish Intercollegiate Guidelines Network (SIGN), December 2005

Purpose: To draw up a guideline for the management of breast cancer

Can be obtained from: SIGN, 28 Thistle Street, Edinburgh EH2 1EN. Tel: 0131 718 5090. SIGN Publication No. 84 December 2005

Link to website: www.sign.ac.uk/guidelines/published/index.html#Cancer

Produced by: BASO (British Association of Surgical Oncology) Breast Speciality Group

Purpose: Guidelines covering all aspects of the breast cancer patient journey relevant to current standard treatments in the NHS. Although the emphasis is on surgery, the guidelines also cover referral, diagnosis, adjuvant treatments, follow up and recurrent disease.

Can be obtained from: BASO, Royal College of Surgeons, 35-43 Lincolns Inn Fields, London WC2A 3PN. Tel: 020 7405 5612.

Link to website: www.baso.org/content/Abs-Guidelines.asp

Produced by: NICE - National Institute for Clinical Excellence, May 2004. Clinical guideline.

Purpose: NICE has issued its clinical guidance on familial breast cancer to the NHS in England and Wales. This information describes the guidance that the NICE has issued to the NHS on assessing a woman's risk of having a type of breast cancer that runs in families (called ‘familial breast cancer’) and on caring for women who are at risk of familial breast cancer.

To be obtained from: Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0561. A patient version of this document can be obtained by quoting ref: N0562. An English and Welsh version of the patient leaflet is also available, ref: N0563.

Link to website: www.nice.org.uk/guidance/cg41

Produced by: Royal College of Obstetricians and Gynaecologists - January 2004

Purpose: Guidelines for the management of women who become pregnant or who are trying to become pregnant before, during, or after treatment for breast cancer.

Link to website (PDF document)

Produced by: NICE - National Institute for Clinical Excellence. Technology appraisal TA062.

Purpose: Guidelines for the use of capecitabine in its licensed indication for breast cancer, relative to current standard treatments in the NHS, and to produce guidance to the NHS in England and Wales.

To be obtained from: Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0226. A patient version of this document can be obtained by quoting ref: N0228. An English and Welsh version of the patient leaflet is also available, ref: N0229.

Link to website: www.nice.org.uk/guidance/TA62

Produced by: NICE - National Institute for Clinical Excellence, December 2002. Technology appraisal TA054.

Purpose: To establish the clinical and cost effectiveness of vinorelbine in its licensed indication for breast cancer, relative to current standard treatments in the NHS, and to produce guidance to the NHS in England and Wales.

To be obtained from: Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0140. A patient version of this document can be obtained by quoting ref: N0142. A bi-lingual patient leaflet is also available, ref: N0143.

Link to website: www.nice.org.uk/44855

Produced by: NICE - National Institute for Clinical Excellence, March 2002. Technology Appraisal Guidance No.34.

Purpose: To establish the clinical and cost effectiveness of trastuzumab in its licensed indication for breast cancer, relative to current standard treatments in the NHS, and to produce guidance to the NHS in England and Wales.

To be obtained from: NHS Response Line on 0870 1555 455, quoting reference N0064. A patient version of this document can be obtained by quoting ref: N0066. A bi-lingual patient leaflet is also available, ref: N0067.

Link to website: www.nice.org.uk/guidance/TA34

Produced by: NICE (National Institute for Clinical Excellence), August 2002

Purpose: This provides guidance to the NHS on the organisation and delivery of services for people with breast cancer.

Can be obtained from: The manual, information for the public, and background documents are available to download from the website.

Link to website: www.nice.org.uk/guidance/csgbc

Produced by: NICE - National Institute for Clinical Excellence, September 2001. Technology Appraisal Guidance No.30

This document replaces the previous guidance on the use of taxanes for breast cancer (Guidance on the use of Taxanes for Breast Cancer: NICE Technology Appraisal Guidance No 6. London: June 2000).

Purpose: To update the previous review by bringing together the most recent reliable data to elucidate the following areas of uncertainty: (i) the use of paclitaxel and docetaxel as first-line treatment of advanced breast cancer and (ii) the use of paclitaxel and docetaxel as second-line treatment of advanced breast cancer.

Can be obtained from: Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0029. A patient version of this document can be obtained by quoting ref: N0031. A bi-lingual patient leaflet is also available, ref: N0032.

Link to website: www.nice.org.uk/guidance/TA30

Produced by: COIN - The Royal College of Radiologists' Clinical Oncology Information Network

Purpose: To help cancer centres and units to form the basis for local protocol development and implementation throughout the UK.

Can be obtained from: www.rcr.ac.uk/index.asp?PageID=667 or Clinical Oncology 11(Supp 3) 1999, ppS89-133.

Produced by: COIN - Faculty of Clinical Oncology of the Royal College of Radiologists

Purpose: To produce evidence-based guidelines for Clinical Oncology.

Can be obtained from: COIN project office, Clinical Oncology Centre, North Middlesex Hospital, London N18 1QX. Tel: 020 8887 2136

Link to website: www.rcr.ac.uk/index.asp?PageID=667

Produced by: BASO (British Association of Surgical Oncology) Breast Speciality Group

Purpose: To promote optimal management of women with breast cancer and bone metastases.

Can be obtained from: European Journal of Surgical Oncology 25 1999, pp3-23 or BASO, Royal College of Surgeons, 35-43 Lincolns Inn Fields, London WC2A 3PN. Tel: 020 7405 5612.

Link to website: www.baso.org/content/Abs-Guidelines.asp

Produced by: The Wessex Institute for Health Research & Development - 1995

Purpose: To provide rapid, accurate and usable information on health technology effectiveness to purchasers, clinicians, managers and researchers.

Can be obtained from: This report has been prepared as part of the Development and Evaluation Service funded by the Research and Development Directorate, NHS Executive. DEC Report No.41. The full text is available on the Internet.

Link to website: www.hta.nhsweb.nhs.uk/rapidhta/publications.htm